Health Catalyst Insider Filing Reveals 207k Shares Held by New CTO
Rhea-AI Filing Summary
Form 3 overview – Health Catalyst, Inc. (HCAT): On 06/25/2025, Chief Technology & Product Officer David Coy Ross filed an initial statement of beneficial ownership. The filing discloses direct ownership of 207,579 common shares, consisting of previously issued stock plus multiple tranches of restricted stock units (RSUs) granted under the 2019 Stock Option and Incentive Plan. The RSUs follow customary quarterly-vesting schedules, with the largest award (90,000 RSUs) beginning to vest on 12/01/2025 (33.33%) and the balance in eight equal quarterly installments. No derivative securities, purchases, or sales were reported; the Form 3 simply records the officer’s existing equity position as required under Section 16(a). The disclosure signals equity alignment between the newly reported executive and shareholders but does not by itself imply any immediate financial impact on HCAT.
Positive
- Alignment of interests: Officer owns 207,579 shares (mostly RSUs), indicating long-term incentive alignment with shareholders.
Negative
- None.
Insights
TL;DR: Routine Form 3; officer holds 207.6k shares via RSUs—neutral governance disclosure.
The filing is a standard Section 16(a) Form 3 indicating that David Coy Ross is now deemed an insider due to his role as Chief Technology & Product Officer. The 207,579-share position (≈0.3% of 74 m shares outstanding) is comprised largely of unvested RSUs that incentivise long-term performance. No open-market transactions, option grants, or derivative positions were disclosed, and vesting schedules match typical tech-sector comp structures. From a governance perspective, the information is neutral: it improves transparency but does not alter capital structure or convey directional intent. Investors should monitor future Forms 4 for any subsequent sales or additional grants.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents an award of restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on September 1, 2022 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments. Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on December 1, 2022 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments. Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on September 1, 2023 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments. Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on December 1, 2024 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments. Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 33.33% of the RSUs will vest on December 1, 2025 and the remaining 66.67% of the RSUs will vest in 8 equal quarterly installments.
